1. Home
  2. SCWO vs MOLN Comparison

SCWO vs MOLN Comparison

Compare SCWO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$0.24

Market Cap

72.8M

Sector

Utilities

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.39

Market Cap

157.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCWO
MOLN
Founded
2021
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Environmental Services
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SCWO
MOLN
Price
$0.24
$4.39
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
1.2M
3.4K
Earning Date
11-12-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,910,340.00
N/A
Revenue This Year
$5,945.19
N/A
Revenue Next Year
$106.82
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
508.52
N/A
52 Week Low
$0.16
$3.36
52 Week High
$1.09
$5.91

Technical Indicators

Market Signals
Indicator
SCWO
MOLN
Relative Strength Index (RSI) 42.52 55.40
Support Level $0.21 $3.98
Resistance Level $0.30 $4.40
Average True Range (ATR) 0.03 0.18
MACD 0.00 -0.01
Stochastic Oscillator 46.95 68.12

Price Performance

Historical Comparison
SCWO
MOLN

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: